Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the companyâs transformative, high precision ophthalmic delivery platform. Eyenoviaâs pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases. Source
No articles found.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing comme...
BioDelivery Sciences International, Inc. (NASDA...
NanoVibronix Inc. is a medical device company that is focused on creating medical ...
NanoVibronix Inc. is a medical device company t...
Allenaâs lead product candidate, reloxaliase, is a first-in-class, oral enzyme t...
Allenaâs lead product candidate, reloxaliase,...
ContraFect is a clinical-stage biotechnology company focused on discovering and de...
ContraFect is a clinical-stage biotechnology co...
We are a late-stage biopharmaceutical company dedicated to bringing transformative...
We are a late-stage biopharmaceutical company d...
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
Join the National Investor Network and get the latest information with your interests in mind.